SA
ABBV icon

Shilanski & Associates’s AbbVie ABBV Stock Holding History

Shilanski & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.68M Sell
20,218
-211
-1% -$43K 1.24% 26
2025
Q2 		$3.79M Sell
20,429
-573
-3% -$106K 1.08% 29
2025
Q1 		$4.4M Sell
21,002
-1,563
-7% -$304K 1.37% 25
2024
Q4 		$4.01M Buy
22,565
+386
+2% +$71K 1.29% 27
2024
Q3 		$4.38M Sell
22,179
-460
-2% -$85.9K 1.42% 26
2024
Q2 		$3.88M Buy
22,639
+298
+1% +$49.4K 1.31% 27
2024
Q1 		$4.07M Buy
22,341
+156
+0.7% +$26.9K 1.4% 25
2023
Q4 		$3.44M Buy
22,185
+103
+0.5% +$15K 1.31% 27
2023
Q3 		$3.29M Buy
22,082
+347
+2% +$50.9K 1.34% 27
2023
Q2 		$2.93M Buy
21,735
+631
+3% +$92.5K 1.18% 31
2023
Q1 		$3.39M Buy
21,104
+212
+1% +$32.4K 1.53% 26
2022
Q4 		$3.38M Buy
20,892
+18,449
+755% +$2.83M 1.48% 26
2022
Q3 		$328K Sell
2,443
-18,675
-88% -$2.68M 0.12% 91
2022
Q2 		$3.23M Buy
21,118
+314
+2% +$48K 1.51% 25
2022
Q1 		$3.37M Sell
20,804
-402
-2% -$58.4K 1.42% 26
2021
Q4 		$2.87M Sell
21,206
-264
-1% -$31.2K 1.22% 34
2021
Q3 		$2.32M Buy
21,470
+416
+2% +$47.5K 1.08% 37
2021
Q2 		$2.37M Buy
21,054
+454
+2% +$51.1K 1.13% 35
2021
Q1 		$2.23M Buy
20,600
+1
+0% +$107 1.19% 35
2020
Q4 		$2.21M Buy
+20,599
New +$1.98M 1.34% 30

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Shilanski & Associates's ABBV Position: Q3 2025 in Review

Shilanski & Associates reduced its AbbVie (ABBV) stake by 1% in Q3 2025, selling an estimated $43K and leaving 20,218 shares worth $4.68M. The position accounts for 1.24% of the portfolio, ranked #26.

Shilanski & Associates first reported a position in ABBV in Q4 2020 and has held it in 20 quarters since. 3,915 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

  • Shilanski & Associates held 20,218 shares of AbbVie worth $4.68M as of Q3 2025.
  • Shilanski & Associates sold 211 AbbVie shares in Q3 2025, an estimated $43K.
  • AbbVie made up 1.24% of Shilanski & Associates's portfolio in Q3 2025, its #26 holding.
  • Shilanski & Associates first reported a position in AbbVie in Q4 2020 and has held it in 20 quarters since.
  • 3,915 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.